Home | Publications | Biotechnology place holder
place holder place holder

Biotechnology

Biomarkers


Publication Date   January 2008
Publisher   RI Technologies
Product Type   Report
Pages   226
ISBN Number   not applicable
Product Code   RIT005
Ask a question about this product?

Price £1,645.00

approximately: $2,841 | €2,089

Summary


This market insight report on Biomarkers focuses on the different types of biomarkers and their impact on various disease areas such as oncology, neurology, cardiology and other areas including metabolomic turmoil, arthritis, gynecology, oxidative stress, liver disease, pulmonary disease and aging. The study provides global market analysis for biomarkers by the above disease areas and also by prominent biomarker discovery technologies including imaging, genomics, proteomics, metabolomics, bioinformatics and other technologies comprising fluorescent indicators, lab-on-chip, nuclear magnetic resonance, mass spectrometry/liquid chromatography and nanobiotechnology. Though the report mentions about non-medical applications of biomarkers, the study emphasizes only on the medical applications. The study includes estimates and projections for the total global biomarkers market. The market covered for genomics, proteomics and bioinformatics pertains only to biomarker discovery applications. Projections and estimates figure for geographic regions including United States, Europe, Japan, Asia-Pacific, Canada and Rest of World. The industry is analyzed in US Dollars and includes 199 exclusive exhibits. A total of 402 companies are covered that are engaged in biomarkers R&D, discovery, testing, and supply of products and services.

Content


  • I. Scope And Methodology
  • II. Report Synopsis
    • 1. Introduction
      • Biomarkers
      • Segmentation of Biomarkers
      • Exhibit 1: Segmentation of Global Biomarkers Market By Discovery Technology (Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other) and Therapeutic Area (Oncology, Cardiology, Neurology and Other)
    • 2. Global Market Analysis
      • Exhibit 2: Biomarkers (2005-2010) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Therapeutic Area Analysis by Geographic Region
      • Oncology
      • Exhibit 3: Biomarkers in Oncology (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 4: Biomarkers in Oncology (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Cardiology
      • Exhibit 5: Biomarkers in Cardiology (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 6: Biomarkers in Cardiology (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
      • Neurology
      • Exhibit 7: Biomarkers in Neurology (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 8: Biomarkers in Neurology (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Other
      • Exhibit 9: Biomarkers in Other Therapeutics (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 10: Biomarkers in Other Therapeutics (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Biomarker Discovery Technology Analysis by Geographic Region
      • Imaging
      • Exhibit 11: Imaging Technologies for Biomarker Discovery (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 12: Imaging Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
      • Genomics
      • Exhibit 13: Genomic Technologies for Biomarker Discovery (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million
      • Exhibit 14: Genomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Proteomics
      • Exhibit 15: Proteomic Technologies for Biomarker Discovery (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 16: Proteomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
      • Metabolomics
      • Exhibit 17: Metabolomic Technologies for Biomarker Discovery (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 18: Metabolomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
      • Bioinformatics
      • Exhibit 19: Bioinformatics for Biomarker Discovery (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 20: Bioinformatics for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Other
      • Exhibit 21: Other Biomarker Discovery Technologies (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 22: Other Biomarker Discovery Technologies (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World
      • Exhibit 23: List of Major Global Companies
    • 3. Regional Market Analysis
      • North America
      • Exhibit 24: Biomarkers (2005-2010) - North American Market Analysis (Current & Future) n US$ Million (Graphical Representation Included)
      • Major Companies in North America
      • Affymetrix, Inc. (USA)
      • Agilent Technologies, Inc. (USA)
      • Applied Biosystems Group (USA)
      • AVIVA Biosciences Corporation (USA)
      • Beckman Coulter, Inc. (USA)
      • BG Medicine, Inc. (USA)
      • BioForce Nanosciences, Inc. (USA)
      • BioMarker Pharmaceuticals, Inc. (USA)
      • Bristol Myers Squibb Co. (USA)
      • Bruker Daltonics, Inc. (USA)
      • Calibrant Biosystems, Inc. (USA)
      • Caprion Pharmaceuticals, Inc. (Canada)
      • Celera Genomics Group (USA)
      • Ciphergen Biosystems, Inc. (USA)
      • Correlogic Systems, Inc. (USA)
      • Eli Lilly and Co. (USA)
      • Fujirebio Diagnostics, Inc. (USA)
      • Gene Logic, Inc. (USA)
      • Genego, Inc. (USA)
      • GeneNews Ltd. (Canada)
      • IBEX Technologies, Inc. (Canada)
      • Iconix Biosciences, Inc. (USA)
      • Large Scale Biology Corporation (USA)
      • Metabolon, Inc. (USA)
      • Monogram Biosciences, Inc. (USA)
      • Pathwork Diagnostics (USA)
      • PerkinElmer, Inc. (USA)
      • Pfizer, Inc. (USA)
      • SomaLogic, Inc. (USA)
      • Thermo Fisher Scientific, Inc. (USA)
      • Upstream Biosciences, Inc. (Canada)
      • Therapeutic Area Analysis by Geographic Region
      • Oncology
      • Exhibit 25: Biomarkers in Oncology (2005-2010) - North American Market Analysis Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 26: Biomarkers in Oncology (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada
      • Cardiology
      • Exhibit 27: Biomarkers in Cardiology (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 28: Biomarkers in Cardiology (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada
      • Neurology
      • Exhibit 29: Biomarkers in Neurology (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 30: Biomarkers in Neurology (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada
      • Other
      • Exhibit 31: Biomarkers in Other Therapeutics (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 32: Biomarkers in Other Therapeutics (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region for United States and Canada
      • Biomarker Discovery Technology Analysis by Geographic Region
      • Imaging
      • Exhibit 33: Imaging Technologies for Biomarker Discovery (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 34: Imaging Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Genomics
      • Exhibit 35: Genomic Technologies for Biomarker Discovery (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 36: Genomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Proteomics
      • Exhibit 37: Proteomic Technologies for Biomarker Discovery (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 38: Proteomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Metabolomics
      • Exhibit 39: Metabolomic Technologies for Biomarker Discovery (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 40: Metabolomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Bioinformatics
      • Exhibit 41: Bioinformatics for Biomarker Discovery (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 42: Bioinformatics for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Other
      • Exhibit 43: Other Biomarker Discovery Technologies (2005-2010) - North American Market Analysis (Current & Future) by Geographic Region for United States and Canada in US$ Million (Graphical Representation Included)
      • Exhibit 44: Other Biomarker Discovery Technologies (2005, 2006 and 2010) - Percentage Breakdown of North American Market Value by Geographic Region United States and Canada
      • Europe
      • Exhibit 45: Biomarkers (2005-2010) - European Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Major Companies in Europe
      • ACE BioSciences A/S (Denmark)
      • Affibody AB (Sweden)
      • Alphalyse A/S (Denmark)
      • Bayer AG (Germany)
      • Biacore International AB (Sweden)
      • BioSense Laboratories AS (Norway)
      • Biotrin International (Ireland)
      • BRAHMS AG (Germany)
      • Dako A/S (Denmark)
      • DxS Ltd. (UK)
      • Epigenomics AG (Germany)
      • GE Healthcare (UK)
      • Genedata AG (Switzerland)
      • GlaxoSmithKline Plc (UK)
      • MDS Pharma Services (UK)
      • Nonlinear Dynamics Ltd. (UK)
      • Novartis AG (Switzerland)
      • Oy Jurilab Ltd. (Finland)
      • Proteome Sciences plc (UK)
      • TheRyte Ltd. (UK)
      • Therapeutic Area Analysis by Geographic Region
      • Oncology
      • Exhibit 46: Biomarkers in Oncology (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 47: Biomarkers in Oncology (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Cardiology
      • Exhibit 48: Biomarkers in Cardiology (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 49: Biomarkers in Cardiology (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Neurology
      • Exhibit 50: Biomarkers in Neurology (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 51: Biomarkers in Neurology (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Other
      • Exhibit 52: Biomarkers in Other Therapeutics (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 53: Biomarkers in Other Therapeutics (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Biomarker Discovery Technology Analysis by Geographic Region
      • Imaging
      • Exhibit 54: Imaging Technologies for Biomarker Discovery (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 55: Imaging Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Genomics
      • Exhibit 56: Genomic Technologies for Biomarker Discovery (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 57: Genomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Proteomics
      • Exhibit 58: Proteomic Technologies for Biomarker Discovery (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 59: Proteomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Metabolomics
      • Exhibit 60: Metabolomic Technologies for Biomarker Discovery (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 61: Metabolomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Bioinformatics
      • Exhibit 62: Bioinformatics for Biomarker Discovery (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 63: Bioinformatics for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Other
      • Exhibit 64: Other Biomarker Discovery Technologies (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
      • Exhibit 65: Other Biomarker Discovery Technologies (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
      • Asia-Pacific
      • Exhibit 66: Biomarkers (2005-2010) -Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
      • Major Companies in Asia-Pacific
      • Human Metabolome Technologies, Inc. (Japan)
      • Proteome Systems Ltd. (Australia)
      • Soiken, Inc. (Japan)
      • Triesta Sciences, Inc. (India)
      • Therapeutic Area Analysis by Geographic Region
      • Oncology
      • Exhibit 67: Biomarkers in Oncology (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 68: Biomarkers in Oncology (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
      • Cardiology
      • Exhibit 69: Biomarkers in Cardiology (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 70: Biomarkers in Cardiology (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Neurology
      • Exhibit 74: Biomarkers in Neurology (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 72: Biomarkers in Neurology (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
      • Other
      • Exhibit 73: Biomarkers in Other Therapeutics (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 74: Biomarkers in Other Therapeutics (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Biomarker Discovery Technology Analysis by Geographic Region
      • Imaging
      • Exhibit 75: Imaging Technologies for Biomarker Discovery (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 76: Imaging Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Genomics
      • Exhibit 77: Genomic Technologies for Biomarker Discovery (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 78: Genomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Proteomics
      • Exhibit 79: Proteomic Technologies for Biomarker Discovery (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 80: Proteomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Metabolomics
      • Exhibit 81: Metabolomic Technologies for Biomarker Discovery (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 82: Metabolomic Technologies for Biomarker Discovery (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Bioinformatics
      • Exhibit 83: Bioinformatics for Biomarker Discovery (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 84: Bioinformatics for Biomarker Discovery (2005, 2006 and 2010) - Percentag Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Other
      • Exhibit 85: Other Biomarker Discovery Technologies (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
      • Exhibit 86: Other Biomarker Discovery Technologies (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific
      • Rest of World
      • Exhibit 87: Biomarkers (2005-2010) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  • III. Product/Technology Research
    • 1. Introduction
      • Biomarkers Growth Trends - Global Markets
      • Exhibit 88: Global Market for Biomarkers: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Biomarker Groups
      • Biomarkers of Exposure
      • Therapeutic Biomarkers
      • Post Genomic Biomarker-Based Products Market
      • Exhibit 89: Post Genomic Biomarker Based Products Market - Global Estimates and Projections for the Period 2005-2010 in US$ Million (Graphical Representation Included)
      • Laboratory Process of Biomarkers Development
      • F2-Isoprostances
      • Reactive Oxygen and Nitrogen Species
      • Biomarkers Associated with Breath Exhaled
      • Application of Biomarkers
      • Medical Sector
      • Non-Medical Sector
      • Categorization of Biomarkers
      • DNA Biomarkers
      • Mitochondrial DNA
      • Inheritance of Mitochondria in Living Organisms
      • Mitochondrion Transformations Leads to Cancer
      • RNA Biomarkers
      • Micro RNAs
      • Gene Biomarkers
      • Metabolic Biomarkers
      • Examining Degradation of Anerobic Hydrocarbon with Metabolic Biomarkers
      • Cell Biomarkers
      • Global Market for Cell Based Therapeutics
      • Exhibit 90: Cell Based Therapeutics Market (2005-2010) - Global Market Analysis (Current & Future) by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Million (Graphical Representation Included)
      • Exhibit 91: Cell Based Therapeutics Market (2005-2010) - Percentage Breakdown of Global Market Value by Therapeutic Area for Central Nervous System (CNS), Cancer Other in US$ Million
      • Single Nucleotide Polymorphism (SNP)
      • Protein Biomarkers
      • Upgrade of Proteins for Biomarkers
      • Protein Biomarkers with Array Technologies
      • Proteomic Studies to Enhance Drug Development Process
      • Biomarkers and Molecular Diagnostics
      • Systems Biology
      • Aim of Systems Biology
      • Omics Technologies based Systems Biology
    • 2. Various Diseases - Role of Biomarkers
      • Growth Trends - Global Biomarker Therapeutic Areas
      • Exhibit 92: Global Market for Biomarkers: Major Biomarker Therapeutic Areas (Cardiology, Neurology and Oncology) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Oncology
      • Growth Trends - Global Market for Biomarkers in Oncology Therapeutics
      • Exhibit 93: Global Market for Biomarkers in Oncology Therapeutics: Geographic Regions (Asia- Pacific, Europe, Japan, Canada, United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Application of biomarkers in Cancer Treatment
      • Cancer Biomarkers
      • Serum Biomarkers
      • Prostate-Specific Antigen
      • Other serum biomarkers
      • Lung Cancer and Biomarkers
      • Features of Biomarkers for Lung Cancer
      • Breast and Ovarian Cancer
      • Colorectal Cancer
      • Hereditary Nonpolyposis Colorectal Cancer
      • Mass Spectrometry - An Emerging Tool for Cancer Biomarker Discovery
      • Role of Chromatography & Mass Spectrometry in Cancer Treatment
      • Mass Spectrometry to Aid Laboratory Methods
      • Global Marker for Mass Spectrometry
      • Exhibit 94: Mass Spectrometry Market - Global Estimates and Projections for the Period 2005-2010 in US$ Million (Graphical Representation Included)
      • Cardiology
      • Growth Trends - Global Market for Biomarkers in Cardiology Therapeutics
      • Exhibit 95: Global Market for Biomarkers in Cardiology Therapeutics: Geographic Regions (Asia-Pacific, Europe, Canada, Japan and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Cardiac Biomarkers - An Overview
      • Renal Insufficiency-Risk of Cardiovascular Disease
      • Global Market for Cardiovascular Diagnostics
      • Exhibit 96: Cardiovascular Diagnostics Market - Global Estimates and Projections for the Period 2005-2010 in US$ Million (Graphical Representation Included)
      • Neurology
      • Growth Trends - Global Market for Biomarkers in Neurology Therapeutics
      • Exhibit 97: Global Market for Biomarkers in Neurology Therapeutics: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Neurodegenerative Diseases
      • Global Neurodegerative Diseases Market
      • Exhibit 98: Neurodegerative Diseases Market - Global Estimates and Projections for the Period 2005-2010 in US$ Million (Graphical Representation Included)
      • Alzheimer€s
      • Parkinson€s
      • Huntington€s
      • Traumatic Brain Injury
      • Other
      • Biomarkers for Detection of Arthritis
      • Rheumatic Arthritis
      • Biomarkers in Gynecology
      • Pre-Eclampsia in Women
      • Protein Biomarker to Understand the Condition of Pre-Eclampsia
      • Pre-Eclampsia€s and Oxidative Stress
      • Role of Biomarkers of Oxidative Stress in Intricate Pregnancies
      • Premenstrual Dysphoric Disorder
      • Analysis of Premenstrual Dysphoric Disorder
      • Premenstrual Syndrome
      • Biomarkers in Analyzing Oxidative Stress
      • Biomarkers to Analyze Oxidative Stress in Lung Disorders
      • Tuberculosis
      • Biomarkers for Detection of SARS Disease
      • Role of Biomarkers in HIV Detection and Analysis
      • Role of Biomarkers in Malaria Treatment
      • Stage I
      • Stage II
      • Stage III or Key Stage
      • Ageing Biomarkers
      • Exhibit 99: Ageing Biomarkers and Their Effect
      • Biomarkers for Detection of Renal Difficulties Leading To Diabetes Mellitus
      • Type 1 diabetes
      • Type -2 diabetes
    • 3. Biomarker Identification Technologies
      • Growth Trends - Global Biomarker Therapeutic Areas
      • Exhibit 100: Global Market for Biomarkers: Major Biomarker Discovery Technologies (Bioinformatics, Genomics, Metabolomics, Proteomics and Imaging) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Imaging Technologies
      • Imaging in Preclinical Studies
      • Imaging Clinical Trials-Cancer
      • Growth Trends - Global Imaging Technologies Market for Biomarkers Discovery
      • Exhibit 101: Global Market for Imaging Technologies for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Major Imaging Technologies
      • Computer Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      • Diffusion MRI techniques
      • Ultrasound or Sonography using MRI
      • Magnetic Resonance Angiography (MRA)
      • Magnetic Resonance Spectroscopy (MRS)
      • Positron Emission Tomography (PET)
      • Method of USAge
      • Genomics
      • Growth Trends - Global Genomics Market for Biomarkers Discovery
      • Exhibit 102: Global Genomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Proteomics
      • Growth Trends - Global Proteomics Market for Biomarkers Discovery
      • Exhibit 103: Global Proteomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • The Key Technologies that are used for Proteomics
      • Matrix Assisted Laser Desorption Ionization (MALDI)
      • Metabolomics
      • Growth Trends - Global Metabolomics Market for Biomarkers Discovery
      • Exhibit 104: Global Metabolomics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • The Crucial Role of Metabolomics in Discovery
      • Biomarkers Discovery and Validation through Urinary Proteomics
      • Urinary Exosomes
      • Bioinformatics
      • Growth Trends - Global Bioinformatics Market for Biomarkers Discovery
      • Exhibit 105: Global Bioinformatics Market for Biomarkers Discovery: Geographic Regions (Asia-Pacific, Japan, Europe, Canada and United States) Ranked by Projected CAGR for 2005 through 2010 (Graphical Representation Included)
      • Other
      • Fluorescent Indicators for Cancer Biomarkers and Neutral Sugars
      • Identification of Biomarkers by Feature Wrappers
      • Nanobiotechnology
      • Biomarkers and Nanoproteins
    • 4. Biomarkers in Drug Discovery/Development
      • Biomarkers Application in Pharma Industry
      • Nuclear Magnetic Resonance Techniques
      • Mass Spectrometry Techniques to Aid the Study of Proteomics
      • Top Down
      • Bottoms Up
      • Genomics Techniques
      • Metabolomics Techniques
      • Devising and Monitoring of Biological Structure
      • Devising of Sensors
      • Data Base Management and Visualization Tools for Bioinformatics
      • Inhalation Toxicology Techniques
      • Varieties of Micro Arrays Employed in Pharmaceutical Sectors
      • Eco Toxicology Techniques
      • Why Pharma/Biotech Industry is Keen in Biomarkers?
      • Application and Benefits of Biomarkers in Drug Development
      • Verification of Biomarkers Applicability
      • Biomarkers Application in Clinical Drug Development
      • Biomarkers Effect on Discovery and Application of a Drug
      • Drug Safety and Role of Biomarkers
      • Toxic Biomarkers to Aid Drug Manufacture
      • Toxicoproteomics
      • PK/PD Biomarkers in Drug Development
    • 5. Product Trends
      • Enhanced Treatment for Spondylarthritis with Innovative Biomarkers
      • A New Diagnostic Marker to Measure Efficiency of Cancer Drug
      • SINE RNA to Emerge as Biomarker for Tobacco Hazards
      • Kinetic Biomarker Enhances Drug Development
      • New Biomarkers to Detect Nephrotoxicity
      • Biomarkers in Combination with Pharmacogenomics
  • IV. Market Dynamics
    • 1. Market Overview
      • Global Market Analysis
      • Exhibit 106: Biomarkers (2005-2010) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World in US$ Million (Graphical Representation Included)
      • Exhibit 107: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Japan, Asia-Pacific, Canada and Rest of World (Graphical Representation Included)
    • 2. Market Trends
      • Biomarkers - An Emerging Trend in Pharma Industry
      • Innovative Biomarker Discovery Methods Aid in Drug Development Stages
      • Biomarkers Becoming Important in Developing Better Drugs
      • Pharma Companies Investing Huge Amounts in Biomarkers Discovery
      • What Pharma Companies Looking in Biomarkers?
    • 3. Major Companies in Biomarker Industry
      • Affibody AB (Sweden)
      • Affymetrix, Inc. (USA)
      • Agilent Technologies, Inc. (USA)
      • Applied Biosystems Group (USA)
      • AVIVA Biosciences Corporation (USA)
      • Bayer AG (Germany)
      • Beckman Coulter, Inc. (USA)
      • BG Medicine, Inc. (USA)
      • Biacore International AB (Sweden)
      • BioForce Nanosciences, Inc. (USA)
      • BioMarker Pharmaceuticals, Inc. (USA)
      • BioSense Laboratories AS (Norway)
      • Biotrin International (Ireland)
      • BRAHMS AG (Germany)
      • Bristol Myers Squibb Co. (USA)
      • Bruker Daltonics, Inc. (USA)
      • Calibrant Biosystems, Inc. (USA)
      • Caprion Pharmaceuticals, Inc. (Canada)
      • Celera Genomics Group (USA)
      • Ciphergen Biosystems, Inc. (USA)
      • Compugen Ltd. (Israel)
      • Correlogic Systems, Inc. (USA)
      • Dako A/S (Denmark)
      • Diagnostics Products Corporation (USA)
      • DxS Ltd. (UK)
      • Eli Lilly and Co. (USA)
      • Epigenomics AG (Germany)
      • Fujirebio Diagnostics, Inc. (USA)
      • GE Healthcare (UK)
      • Gene Logic, Inc. (USA)
      • Genedata AG (Switzerland)
      • Genego, Inc. (USA)
      • GeneNews Ltd. (Canada)
      • Human Metabolome Technologies, Inc. (Japan)
      • IBEX Technologies, Inc. (Canada)
      • Iconix Biosciences, Inc. (USA)
      • Large Scale Biology Corporation (USA)
      • MDS Pharma Services (UK)
      • Metabolon, Inc. (USA)
      • Monogram Biosciences, Inc. (USA)
      • Nonlinear Dynamics Ltd. (UK)
      • Novartis AG (Switzerland)
      • Oy Jurilab Ltd. (Finland)
      • Pathwork Diagnostics (USA)
      • PerkinElmer, Inc. (USA)
      • Pfizer, Inc. (USA)
      • Proteome Sciences plc (UK)
      • Proteome Systems Ltd. (Australia)
      • Soiken, Inc. (Japan)
      • SomaLogic, Inc. (USA)
      • TheRyte Ltd. (UK)
      • Triesta Sciences, Inc. (India)
      • Upstream Biosciences, Inc. (Canada)
    • 4. Major Activities in Biomarker Industry
      • BD Acquires TriPath
      • Genetix Acquires Applied Imaging Corp
      • Bruker Daltonics Expands Biomarker Discovery Collaboration with HealthLinx
      • Rules-Based Medicine Merges with Multiplex Biosciences
      • Caprion Pharmaceuticals and Vertex Pharmaceuticals Expand Biomarker Discovery Collaboration
      • Bio-Rad Acquires Ciphergen€s Life Science Business
      • Iconix Changes Corporate Identity
      • Lumera Extends Collaboration with Institute for Systems Biology
      • Tandem Labs Takes Over PharmaKD
      • Axela Collaborates with Abnova to Develop Biomarker Panels
      • Genstruct Extends Agreement GlaxoSmithKline
      • Epigenomics AG Signs R&D Agreement with Johnson & Johnson
      • Siemens Acquires Diagnostic Products Corp
      • PerkinElmer and University of Leicester Signs Research Agreement
      • Asterand Enters into Partnership with Rubicon
      • Applied Biosystems Collaborates with SAIC-Frederick
      • PPD Signs Agreement with PDL BioPharma
      • ART Acquires Alerion Biomedical
      • Varian Acquires IonSpec Corp.
      • BD Takes Over GeneOhm
      • Cytomyx Partners with OrigGene
      • Merck Signs Agreement with FoxHollow Technologies
      • Wyeth Expands Collaboration with Caprion
      • Compugen Enters into Collaboration with Ortho-Clinical Diagnostics
      • BioSystems International Signs Agreement with Euroscreen
      • PPD Takes Over SurroMed
      • GeneOhm and Infectio Diagnostic Merge
      • ProteoGenix Collaborates with Bruker Daltonics
      • Invitrogen Acquires Protometrix
    • 5. Major Product Innovations/Launches in Biomarker Industry
      • Fluidigm Launches Biomark System
      • OXIS Launches New Reagents and Antibodies
      • OGeS and Oxford University Develops Novel Biomarkers
      • ART Launches Fenestra
      • Agilent Launches Liquid Chromatography (LC) Column
      • Bruker Daltonics Launches Molecular Imager
      • Waters Enhances ProteinLynx
      • Beckman Coulter Upgrades ProteomeLab
      • GeneData Launches Expressionist Pro 3.0
      • GenoLogics Enhances ProteusLIMS
      • Nonlinear Launches Progenesis PG600
      • Bruker Daltonics Upgrades ClinProt
      • PekinElmer Launches BioXPRESSION
      • BioGenex Unveils Xmatrx
      • Waters Introduces MassTrak Clinical Solutions
      • Bruker Daltonics Launches Clinical Proteomics System
      • Fujirebio Diagnostics Introduces Blood Test for Mesothelioma
      • Millipore Introduces New Sample Preparation Solution for Biomarker Discovery
      • Applied Imaging Launches Ariol 2.0
    • 6. Regional Market Analysis
      • A. The United States
        • Market Analysis
        • Exhibit 108: Biomarkers (2005-2010) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 109: List of Major Companies in the United States
        • Analysis by Therapeutic Area
        • Exhibit 110: Biomarkers (2005-2010) - United States Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 111: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of United States Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other (Graphical Representation Included)
        • Analysis by Biomarker Discovery Technology
        • Exhibit 112: Biomarkers (2005-2010) - United States Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 113: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of United States Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
      • B. Europe
        • Market Analysis
        • Exhibit 114: Biomarkers (2005-2010) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 115: List of Major Companies in Europe
        • Analysis by Geographic Region
        • Exhibit 116: Biomarkers (2005-2010) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe in US$ Million (Graphical Representation Included)
        • Exhibit 117: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, Italy, France, Spain, Switzerland, Belgium, Sweden and Rest of Europe
        • Analysis by Therapeutic Area
        • Exhibit 118: Biomarkers (2005-2010) - European Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 119: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
        • Analysis by Biomarker Discovery Technology
        • Exhibit 120: Biomarkers (2005-2010) - European Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 121: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of European Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
        • European Biomarkers Market By Country
        • B1. Germany
        • B2.The United Kingdom
        • B3. Italy
        • B4. France
        • B5. Spain
        • B6. Switzerland
        • B7. Belgium
        • B8. Sweden
        • B9. Rest of Europe
      • C. Japan
        • Market Analysis
        • Exhibit 158: Biomarkers (2005-2010) - Japanese Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 159: List of Major Companies in Japan
        • Analysis by Therapeutic Area
        • Exhibit 160: Biomarkers (2005-2010) - Japanese Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 161: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Japanese Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
        • Analysis by Biomarker Discovery Technology
        • Exhibit 162: Biomarkers (2005-2010) - Japanese Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 163: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Japanese Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
      • D. Asia-Pacific
        • Market Analysis
        • Exhibit 164: Biomarkers (2005-2010) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 165: List of Major Companies in Asia-Pacific
        • Analysis by Geographic Region
        • Exhibit 166: Biomarkers (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for China, India, Australia and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
        • Exhibit 167: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for China, India, Australia and Rest of Asia-Pacific (Graphical Representation Included)
        • Analysis by Therapeutic Area
        • Exhibit 168: Biomarkers (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 169: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
        • Analysis by Biomarker Discovery Technology
        • Exhibit 170: Biomarkers (2005-2010) - Asia-Pacific Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 171: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Asia-Pacific Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other
        • Asia-Pacific Biomarkers Market By Country
        • D1. China
        • D2. India
        • D3. Australia
        • D4. Rest of Asia-Pacific
      • E. Canada
        • Market Analysis
        • Exhibit 188: Biomarkers (2005-2010) - Canadian Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 190: Biomarkers (2005-2010) - Canadian Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 191: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Canadian Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
        • Analysis by Biomarker Discovery Technology
        • Exhibit 192: Biomarkers (2005-2010) - Canadian Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 193: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Canadian Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other (Graphical Representation Included)
      • F. Rest of World
        • Market Analysis
        • Exhibit 194: Biomarkers (2005-2010) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
        • Exhibit 195: List of Major Companies in Rest of World
        • Analysis by Therapeutic Area
        • Exhibit 196: Biomarkers (2005-2010) - Rest of World Market Analysis (Current & Future) by Therapeutic Area for Oncology, Cardiology, Neurology and Other in US$ Million (Graphical Representation Included)
        • Exhibit 197: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Rest of World Market Value by Therapeutic Area for Oncology, Cardiology, Neurology and Other
        • Analysis by Biomarker Discovery Technology
        • Exhibit 198: Biomarkers (2005-2010) - Rest of World Market Analysis (Current & Future) by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics, Bioinformatics and Other in US$ Million (Graphical Representation Included)
        • Exhibit 199: Biomarkers (2005, 2006 and 2010) - Percentage Breakdown of Rest of World Market Value by Discovery Technology for Imaging, Genomics, Proteomics, Metabolomics Bioinformatics and Other (Graphical Representation Included)
    • 7. Biomarkers - The Industry Outlook
  • V. Corporate Directory